Dry Macular Degeneration

Inclusion Criteria:
- At least 60 years of age with a clinical diagnosis of GA of the macular secondary to AMD.
- GA lesion must be at least 2.5 mm² and no more than 17.5 mm².
- ETDRS score of 24 letters of better (approximately Snellen equivalent of at least 20/320).

Exclusion Criteria:
- GA secondary to a condition other than AMD in either eye.
- Spherical equivalent of the refractive error demonstrating more than six diopters of myopia.
- Any history or active choroidal neovascularization.
- Prior participation in another interventional clinical study for intravitreal therapies in either eye.
- History of prior intravitreal injection in the study eye.

Phase III, multi-center, randomized, double-masked, sham-controlled study to compare the efficacy and safety of intravitreal APL-2 therapy with sham injections in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Principal Investigator
Dr. Matthew Ohr

Contact
Havener Eye Institute Research Office • 614-293-5287 • Research@osumc.edu

This research is not being conducted by the Columbus Chalmers P. Wiley Ambulatory Care Center. The research has not been reviewed by the Institutional Review Board of the Chalmers P. Wiley VA. The VA is not responsible for any costs incurred by participating in the research study.